Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Mexico signs deal with Pfizer for 34.4 million doses of COVID-19 vaccine

12/02/2020 | 03:48pm EST

MEXICO CITY, Dec 2 (Reuters) - Mexico has signed an agreement with Pfizer to acquire 34.4 million doses of its COVID-19 vaccine, the country's health ministry announced on Wednesday.

Mexico expects to receive 250,000 doses in the month of December and will prioritize vaccinating health care workers, the ministry said in a tweet showing Health Minister Jorge Alcocer signing a document.

"What many assumed impossible is now a reality: vaccination is about to start in December 2020," Mexico's foreign minister Marcelo Ebrard said in a tweet earlier on Wednesday.

The United Kingdom approved Pfizer's vaccine on Wednesday, jumping ahead of the rest of the world in the race to begin vaccination.

In Mexico, Pfizer submitted the details about its vaccine to the country's health regulator, Cofepris, last month and is still awaiting approval.

Mexico's President Andres Manuel Lopez Obrador said in his regular morning news conference on Wednesday that Cofepris would work "day and night" to grant vaccine approval "as fast as possible." (Reporting by Miguel Gutierrez and Sharay Angulo, writing by Laura Gottesdiener; Editing by Frank Jack Daniel)

© Reuters 2020
All news about PFIZER INC.
03:55aSwiss to get Moderna vaccine in tranches until mid-year - Blick
01/16PFIZER : Canada surpasses 700,000 confirmed COVID-19 cases as provinces revisit ..
01/16PFIZER : Ontario reports 3,056 new COVID-19 cases, adjusts vaccine schedule due ..
01/15PFIZER : Biden to Outline Plans for Bigger Federal Role in Covid-19 Vaccinations..
01/15PFIZER : Statement by Pfizer Chairman and CEO Albert Bourla
01/15Pfizer says it has second doses of COVID-19 shot on hand, expects no U.S. sup..
01/15Canadian dollar drops, posts weekly decline on greenback short-covering
01/15PFIZER : Vaccine Shortfall to Hit Europe, Canada as Pfizer Plant Is Upgraded
01/15Pfizer says it has second doses of COVID shot on hand, expects no supply prob..
01/15PFIZER : Anger in states over pace of COVID-19 vaccine allotments
More news
Financials (USD)
Sales 2020 48 571 M - -
Net income 2020 17 066 M - -
Net Debt 2020 43 571 M - -
P/E ratio 2020 13,3x
Yield 2020 3,92%
Capitalization 204 B 204 B -
EV / Sales 2020 5,10x
EV / Sales 2021 4,44x
Nbr of Employees 88 300
Free-Float 59,1%
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 41,94 $
Last Close Price 36,70 $
Spread / Highest target 44,4%
Spread / Average Target 14,3%
Spread / Lowest Target -1,91%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-0.30%203 993
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
ABBVIE INC.3.15%195 120